Nutrition & Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Nutrition Department, Faculty of Paramedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Respir Res. 2019 Feb 22;20(1):39. doi: 10.1186/s12931-019-0998-x.
Asthma is a heterogeneous disease which is usually associated with chronic airway inflammation. Saffron has anti-inflammatory effects and may has beneficial effects on asthma.
The present study was intended to survey the effects of saffron supplementation on blood pressure, lipid profiles, basophils, eosinophils and clinical symptoms in patients with allergic asthma.
Our study was a clinical trial.
Subjects (N = 80, 32 women and 48 men, 41.25 ± 9.87 years old) with mild and moderate allergic asthma were randomized into two groups: the intervention group who received two capsules of saffron (100 mg/d), and the control group who received two capsules of placebo for 8 weeks. SPSS software (version 16.0) was used for the data analysis.
Saffron improved the frequency of clinical symptoms of the patients (i.e., frequency of the shortness of breath during the day and night time, use of salbutamol spray, waking up due to asthma symptoms and activity limitation) in comparison to the placebo (p < 0.001). Besides, asthma severity decreased almost significantly in the saffron group (p = 0.07). It was also found that saffron, in comparison with the placebo, significantly reduced the systolic and diastolic blood pressure, triglycerides and low density lipoprotein cholesterol. Moreover, eosinophils and basophils concentration reduced in the saffron group (p = 0.06 and 0.05 respectively).
Saffron seems to be an effective and safe option (in 8 weeks supplementation) to improve clinical symptoms of patients with allergic asthma but the toxicity and/or long-term effects of saffron intake are not known. Registration ID in IRCT (IRCT2017012132081N2).
哮喘是一种异质性疾病，通常与慢性气道炎症有关。藏红花具有抗炎作用，可能对哮喘有益。
本研究旨在调查藏红花补充剂对过敏性哮喘患者血压、血脂谱、嗜碱性粒细胞、嗜酸性粒细胞和临床症状的影响。
我们的研究是一项临床试验。
将 80 名（32 名女性和 48 名男性，年龄 41.25±9.87 岁）轻度和中度过敏性哮喘患者随机分为两组：干预组每天服用 2 粒藏红花（100mg/d），对照组服用 2 粒安慰剂 8 周。使用 SPSS 软件（版本 16.0）进行数据分析。
与安慰剂相比，藏红花改善了患者的临床症状发作频率（即白天和夜间呼吸困难的频率、沙丁胺醇喷雾的使用、因哮喘症状而醒来和活动受限）（p<0.001）。此外，藏红花组的哮喘严重程度几乎明显下降（p=0.07）。还发现，与安慰剂相比，藏红花显著降低了收缩压和舒张压、甘油三酯和低密度脂蛋白胆固醇。此外，藏红花组嗜酸性粒细胞和嗜碱性粒细胞浓度降低（p=0.06 和 0.05 分别）。
藏红花似乎是一种有效且安全的选择（在 8 周的补充期内），可以改善过敏性哮喘患者的临床症状，但藏红花摄入的毒性和/或长期影响尚不清楚。注册号在 IRCT（IRCT2017012132081N2）。
